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BACKGROUND: Original sevoflurane (Sevo A) is made with water, while a generic sevoflurane (Sevocris) is produced with 
propylene glycol as a stabilizing additive. We investigated whether the original and generic sevoflurane preparations differed in 
terms of their minimum alveolar concentration (MAC) values and hemodynamic effects. 
METHODS: Sixteen pigs weighing 31.6±1.8 kg were randomly assigned to the Sevo A or Sevocris groups. After anesthesia in-
duction via mask with the appropriate sevoflurane preparation (6% in 100% oxygen), the MAC was determined for each animal. 
Hemodynamic and oxygenation parameters were measured at 0.5 MAC, 1 MAC and 1.5 MAC. Histopathological analyses of lung 
parenchyma were performed.
RESULTS: The MAC in the Sevo A group was 4.4±0.5%, and the MAC in the Sevocris group was 4.1±0.7%. Hemodynamic and 
metabolic parameters presented significant differences in a dose-dependent pattern as expected, but they did not differ between 
groups. Cardiac indices and arterial pressures decreased in both groups when the sevoflurane concentration increased from 0.5 to 
1 and 1.5 MAC. The oxygen delivery index (DO2I) decreased significantly at 1.5 MAC.
CONCLUSION: Propylene glycol as an additive for sevoflurane seems to be as safe as a water additive, at least in terms of he-
modynamic and pulmonary effects. 
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INTRODUCTION
Sevoflurane is a fluorinated hydrocarbon that stands out 
among today’s inhaled anesthetics due to its low solubility 
(blood: gas partition coefficient of 0.68), non-irritating 
effects on the respiratory tract and pleasant smell. These 
properties allow for rapid and smooth anesthesia induction 
even without pre-medication and offer good control over the 
depth of anesthesia, a factor that is important in patients with 
compromised hemodynamic status.1
Depending on storage and usage conditions, sevoflurane 
can be degraded into different compounds, including the 
highly pungent hydrofluoric acid, a substance known 
to be nephrotoxic and irritating to the respiratory tract 
mucous membrane. This sevoflurane decomposition 
reaction involves a metallic impurity, an acid (a Lewis 
acid) and a substance capable of receiving an electron 
pair to trigger the decomposition reaction. A number of 
compounds, both organic and inorganic, including H2O, 
butylated hydroxytoluene, methylparaben, propylparaben, 
propofol and thymol, can inhibit the Lewis acid reaction. 
A liquid additive (water) was developed as a stabilizer to 
the original sevoflurane (Sevorane®, Abbott) to prevent the 
production of the inorganic fluorides. Cristália Laboratories 
developed a new sevoflurane formula (Sevocris®, Cristalia, 
São Paulo) containing 0.026% p/p of propylene glycol 
as a stabilizer.2 This new product was introduced into the 
Brazilian market in September 2004, after being granted 532
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the approval of ANVISA, Brazil’s Regulatory Agency. 
Propylene glycol is a product utilized in several medications, 
via different routes, and has been considered a GRAS 
product (Generally Recognized as Safe) by the US Food 
and Drug Administration.3 It can be used as an antimicrobial 
preservative, disinfectant, humectant, solvent, vitamin 
stabilizer and water-miscible co-solvent. 
Given this information, we conducted a comparative 
study of sevoflurane with water additive versus with 
propylene glycol additive under experimental conditions in 
pigs. We compared the MAC, hemodynamic and metabolic 
effects and relevant lung histopathological analyses.
MATERIALS AND METHODS
The study protocol and design were approved by the 
Ethics and Animal Investigation Committee at our institution 
and were performed according to the recommendations of 
the National Institutes of Health guidelines for ethical animal 
research. Sixteen young male Large White x Landrace pigs 
weighing 30 to 35 Kg (31.6±1.8 Kg) were fasted overnight 
with free access to water and were randomly assigned to the 
Sevo A or Sevocris groups. After induction of anesthesia via 
mask with the assigned sevoflurane (6% in 100% oxygen), 
animals were orally intubated (7 mm internal diameter 
cuffed endotracheal tube, Hi-Lo, National Catheter, Argyle, 
NY). The lungs were mechanically ventilated (Primus, 
Dräger Medical, Lubeck, Germany) using volume-controlled 
ventilation, 40% FiO2, tidal volume of 8 mL/kg, PEEP of 
5 cmH2O, which was the respiratory frequency adjusted to 
keep end-tidal CO2 between 35 and 45 mmHg. Anesthesia 
was maintained with 5% sevoflurane in 40% oxygen.
A continuous infusion of lactated Ringer (Baxter, 
São Paulo, Brazil) was provided at a rate of 5 mL.kg-1.h-1 
throughout all experiments. The temperature was maintained 
within normal limits for pigs (38.7-39.9°C) using warm 
blankets (Medi-therm II, Gaymar Industries, Orchard Park, 
NY, USA).
Instrumentation
After local anesthetic infiltration (10 mL 2% lidocaine 
with vasoconstrictor), the right femoral artery was surgically 
exposed and catheterized for arterial pressure measurements 
and blood collection. The right jugular vein was also 
catheterized with a pulmonary artery catheter (7.5 F Edwards 
CCO catheter connected to Edwards Vigilance CCO 
Monitor; Edwards Lifesciences Corp., Irvine, CA, USA). 
The position of the pulmonary artery catheter was confirmed 
by typical waveforms. All intravascular catheters were 
zeroed to atmospheric pressure. The midpoint between the 
anterior and posterior chest walls was taken as the zero 
reference point for pressure measurements.
 The STAT-Mode of the Edwards Vigilance CCO 
Monitor was used in each experiment, which displayed 
the actual cardiac output values registered over the past 60 
seconds. The last five measurements of CO were averaged. 
The electrocardiogram and intravascular pressures, mean 
arterial pressure (MAP), mean pulmonary artery pressure 
(MPAP), pulmonary artery wedge pressure (PAWP) and 
central venous pressure (CVP) were monitored continuously 
(MP40, Philips). Numerical values of intravascular pressures 
from the monitor screen were recorded at established points 
of the protocol. After instrumentation, animals were allowed 
to stabilize for 60 minutes.
Hemodynamic indices
The derivative indexes were recorded directly from 
monitors during the experiment: the pulmonary vascular 
resistance index (PVRI), systemic vascular resistance 
index (SVRI), right and left ventricular stroke work index 
(RVSWI and LVSWI), right stroke volume index, (RSVI), 
right ventricle ejection fraction (RVEF) and right ventricular 
end-diastolic volume (RVEDV). The cardiac index (CI) was 
calculated according to calculated body surface (k.BW2/3, 
where k = 0.09, BW=body weight).4, 5
Venous admixture and oxygenation indices
Arterial and mixed venous blood samples were collected 
for pH, partial pressure of arterial oxygen (PaO2), partial 
pressure of arterial carbon dioxide (PaCO2), arterial 
oxygen saturation (SaO2), partial pressure of mixed venous 
oxygen (PvO2) and mixed venous saturation (SvO2) (ABL 
555; Radiometer, Copenhagen, Denmark). The oxygen 
delivery index (DO2I), oxygen consumption index (VO2I) 
and extraction ratio (O2ER) were calculated utilizing 
conventional formulas. 
Determination of MAC
The method for the determination of MAC in this study 
has been described elsewhere.6,7
The end-tidal concentration of sevoflurane was 
maintained at the intended level for a 15 min equilibration 
period. After 15 min of equilibration, the pig was stimulated 
on a dew claw with a hemostat clamped to a full ratchet 
lock for 60 s. The leg was moved back and forth. If there 
were no purposeful movements in response to the stimulus 
(withdrawal of the clamped foot or gross movements 
of either legs or head), the end-tidal sevoflurane was 533
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decreased by 10%, and the protocol was repeated following 
a 15 min anesthetic equilibration period. If there was 
purposeful movement in response to the stimulation, the 
end-tidal concentration was increased by 5%, and following 
equilibration, the stimulation was repeated. The site of the 
stimulations was changed slightly to prevent sensitization 
or desensitization to subsequent stimuli. The expiratory 
concentration of the agent halfway between that allowing 
and that not allowing movement in response was the MAC 
of that agent for each specific animal. 
After MAC determination, systemic hemodynamics, 
respiratory data and blood gases were collected at 0.5, 1.0 
and 1.5 MAC, observing a 15 min equilibrium period after 
each concentration change.
Histopathological analysis 
At the end of the experiment, while still under anesthesia, 
animals received a 1-g bolus of thiopental followed by 25 
mEq of potassium chloride. Lung samples were collected 
from the left diaphragmatic lobe (from zones 1, 2 and 3). 
A sample from the middle portion of the trachea was also 
collected. The lung and trachea samples were prepared for 
optical analyses, fixed in 10% formaldehyde and stained 
with hematoxylin and eosin.
The pathologist, who was blinded to the experimental 
protocol, described the analysis according to the combined 
assessment of neutrophils, eosinophils, mastocytes, and 
mononuclear cell accumulation, pulmonary interstitial 
edema, alveoli collapse, and congestion in the prepared 
sample  lamina  using  an  optical  microscope  at  a 
magnification of 10x. In a subjective manner, the observer 
quantified the positive findings in the samples from different 
regions of the lung as none (0), discrete (1), moderate (2), 
or intense (3). 
Statistical analysis
MAC values were analyzed using the Student´s t-test. 
Hemodynamic and other parametric data were analyzed 
within groups and between groups using an analysis of 
variance (ANOVA) for repeated measurements with two 
factors (SigmaStat 3.11, Systat Software Inc, San Jose, 
USA). When appropriate, post hoc analyses were performed 
with the Tukey test. P<0.05 was considered statistically 
significant. Values are presented as means (SD).
RESULTS
The MAC for the Sevo A group was 4.4% (0.5), whereas 
it was 4.1% (0.7) for the Sevocris group. Body weights, 
MAC values and times to achieve sternal recumbence and to 
orotracheal intubation are presented in Table 1.
Hemodynamic, respiratory and oxygenation parameters 
are described in Tables 2 and 3.
Hemodynamic  parameters  presented  significant 
differences in a dose-dependent pattern as expected, 
but did not differ between groups. Cardiac indices 
decreased significantly in both groups when the sevoflurane 
concentration increased from 0.5 to 1 and 1.5 MAC. We 
also observed a significant decrease in blood pressure 
and mean pulmonary artery pressure at all concentrations 
compared to 0.5 MAC. Heart rate decreased significantly 
when MAC was augmented from 0.5 to 1.0 and 1.5, but the 
values remained in the physiological range for this group of 
animals, and bradycardia was not verified. SvO2 and DO2I 
decreased significantly at 1.5 MAC when compared to 0.5 
and 1.0 MAC. 
Regarding histopathological analyses, no evidence of 
neutrophils, eosinophils, mastocytes, mononuclear cell 
accumulation, pulmonary interstitial edema, alveoli collapse, 
or congestion was found in lung optical microscopy of both 
groups. Also, no histopathological changes were found in 
the trachea. 
DISCUSSION
The main finding in this study was that hemodynamic 
and metabolic responses at equipotent doses were similar 
between water-added sevoflurane (Sevo A) and propylene 
glycol-added sevoflurane (Sevocris).
Under the conditions of this study, the MAC of Sevo A 
was 4.4% (0.5), and the MAC of Sevocris was 4.1% (0.7). 
These values are higher than most published reports, in 
which sevoflurane MAC values range between 2.1% and 
4.4% in pigs.8-13 
Several factors may account for the variations in 
published sevoflurane MAC values, including different 
age groups of pigs, body temperature, pre-anesthetic and 
induction agents, the type and site of noxious stimulus 
and the defined end-point for determination of purposeful 
Table 1 - Body weight, MAC, time to sternal recumbency 
and orotracheal intubation. 
Sevo A Sevocris
Body weight (kg) 31.3 (1.9) 31.9 (1.9)
MAC (%) 4.4 (0.5) 4.1 (0.7)
Sternal recumbency (s) 116 (96) 112 (36)
Orotracheal intubation (s) 659 (433) 620 (275)
Mean (SD)534
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movement in response to the applied stimulus (Table 4). 6, 7, 
14 The stimulus applied in our study was dewclaw clamping, 
which has been reported to be a supramaximal stimulus6 
and which remained constant during the entire study. The 
site of stimulus was changed slightly between stimulations 
to prevent sensitization or desensitization to subsequent 
stimuli. In the study of Hecker,10 where the pigs had almost 
the same weight and were submitted to the same nociceptive 
stimulation as in the present study, the MAC was lower, 
which may have been due to the previous use of azaperone 
and propofol. Holmström and Åkeson,13 in animals weighing 
20.1± 0.7 kg, obtained a MAC of 4.4 90 minutes after 
propofol administration, which is the same value reported 
in the present investigation. On the other hand, Moeser et 
al.,12 studying animals weighing 19 ±0.4 kg and with no 
other agent than sevoflurane, obtained a MAC of 3.5±0.17. 
In the present investigation, weight, age, sex, and stimuli 
were similar in both groups, demonstrating that the two 
anesthetics showed the same behavior with regard to MAC. 
The hemodynamic results are close to those described in 
the literature for sevoflurane. In healthy human volunteers 
and in dogs, the cardiac index, arterial pressure and 
pulmonary arterial pressure decrease in a dose-dependent 
manner.15,16 In infants, sevoflurane did not alter the cardiac 
index at any concentration compared to awake values but 
significantly decreased blood pressure and systemic vascular 
resistance compared to awake values at all concentrations.17 
Special focus has been given to the effects of volatile 
anesthetics on heart rate because desflurane (and to a 
lesser extent isoflurane) can initiate major increases in 
heart rate that might predispose select patient populations 
to myocardial ischemia.18 The results with sevoflurane are 
conflicting, varying across different species, age groups and 
anesthetic techniques. Sevoflurane has not been associated 
with increases in heart rate in healthy volunteers, in 
patients,19 or in children.17 Bernard et al.,16 in dogs, noted 
Table 2 - Hemodynamic data. 
Group 0.5 MAC 1.0 MAC 1.5 MAC
CI (L/min/m2) Sevo A 5.5 (1.3) * 4.2 (0.8) 3.2 (1.0) * †
Sevocris 6.2 (0.7) * 4.7 (1.1) 3.6 (1.2) * †
HR (beat/min) Sevo A 129 (20) 122 (17) 110 (16) * †
Sevocris 138 (19) * 115 (15) 104 (13) †
MAP (mmHg) Sevo A 81 (15) * 66 (7) 45 (10) * †
Sevocris 90 (17) * 68 (10) 52 (11) * †
CVP (mmHg) Sevo A 8 (2) 9 (2) 9 (2)
Sevocris 7 (2) * 9 (1) 10 (1) †
MPAP (mmHg) Sevo A 23 (3) * 21 (2) 19 (3) * †
Sevocris 22 (3) * 21 (3) 20 (3) †
PAWP (mmHg) Sevo A 11 (2) 12 (2) 12 (1)
Sevocris 11 (1) 11 (1) 12 (2)
SVRI (dynes.sec/cm5/m2) Sevo A 1076 (211) 1106 (185) 896 (201) * †
Sevocris 1080 (201) 1047 (260) 959 (193)
PVRI (dynes.sec/cm5/m2) Sevo A 171 (34)  183 (30) 187 (61) 
Sevocris 153 (35)  165 (41) 184 (63) 
LVSWI (gm-m/m2/beat) Sevo A 41 (12) * 26 (6) 13 (6) * †
Sevocris 47 (13) * 33 (6) 20 (9) * †
RVSWI (gm-m/m2/beat) Sevo A 8 (2) * 6 (1) 4 (2) * †
Sevocris 9 (1) * 7 (2) 5 (2) * †
SVI (mL/m2/beat) Sevo A 44 (9) * 34 (5) 28 (6) * †
Sevocris 45 (6) 41 (8) 34 (9) * †
EDVI (mL/m2) Sevo A 159 (33) 157 (52) 156 (58)
Sevocris 162 (30) 148 (19) 146 (11)
Mean (SD); CI=cardiac index; HR=heart rate; MAP=mean arterial pressure; CVP=central venous pressure; MPAP=mean pulmonary artery pressure; 
PCWP=pulmonary artery wedge pressure; SVRI=systemic vascular resistance index; PVRI=pulmonary vascular resistance index; LVSWI=left ventricular 
stroke work index; RVSWI=right ventricular stroke work index; SVI=stroke volume index; EDVI=right ventricular end-diastolic volume index. * P<0.05 
compared to 1 MAC; † P<0.05 compared to 0.5 MAC.535
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significant increases in heart rate from the awake state 
during the administration of 1.2-2.0 MAC. In the present 
study, heart rate decreased when the MAC was augmented 
from 0.5 to 1.0 and 1.5, but the values obtained remained 
in the physiological range for this group of animals, and 
bradycardia was not verified. 
The effects of both tested sevofluranes on cardiac 
performance (LVSWI, RVSWI, SVI and EDVI) were the 
same and are in accordance with the literature. The influence 
of sevoflurane on performance of the right ventricle (RV) 
was studied by Kerbaul and colleagues, who observed a 
significant decrease in the RV stroke work with 1 and 1.5 
MAC of sevoflurane. 20
Ventilation was kept constant in order to maintain the 
Table 3 - Respiratory and oxygenation data. 
Group 0.5 MAC 1.0 MAC 1.5 MAC
RR (mpm) Sevo A 19 (2)  19 (2) 19 (2)
Sevocris 20 (2) 20 (2) 20 (2)
P Peak (cmH2O) Sevo A 22 (3) 21 (3) 21 (3)
Sevocris 20 (4) 20 (3) 20 (3)
P Plato (cmH2O) Sevo A 20 (3) 20 (3) 20 (3)
Sevocris 19 (3)  19 (3) 19 (3)
ComplDyn (mL/cmH2O) Sevo A 23 (5) * 26 (6) 27 (6) †
Sevocris 24 (5) 26 (4) 26 (5)
Vt (mL)  Sevo A 339 (22) * 359 (29) 370 (39) * †
Sevocris 335 (22) * 350 (28) 362 (22) * †
EtCO2 (mmHg) Sevo A 44 (2) 43 (2) 41 (2) * †
Sevocris 44 (2) 43 (4) 41 (4) †
pH art Sevo A 7.454 (0.024) 7.463 (0.026) 7.477 (0.025)
Sevocris 7.464 (0.024) 7.472 (0.041) 7.459 (0.060)
PaCO2 (mmHg) Sevo A 45 (2) 44 (3) 40 (5)
Sevocris 44 (2) 43 (5) 42 (8)
PaO2 (mmHg) Sevo A 174 (36) 166 (40) 160 (43)
Sevocris 181 (20)  162 (27) 157 (33) 
SaO2 (%) Sevo A 99.2 (0.5) 99.0 (0.5) 98.9 (0.9)
Sevocris 99.4 (0.2) 99.1 (0.4) 99.0 (0.7) †
Lactate (mmol/L) Sevo A 1.1 (0.3) 1.1 (0.3) 1.5 (1.0)
Sevocris 1.0 (0.2) 1.1 (0.3) 1.3 (0.3)
PvO2 (mmHg) Sevo A 47 (5) 45 (6) 36 (5) * †
Sevocris 50 (3) * 45 (5) 38 (6) * †
SvO2 (%) Sevo A 77.3 (7.3) 76.1 (7.3) 62.5 (14.7) * †
Sevocris 81.6 (3.9) 76.0 (6.2) 64.7 (12.4) * †
DO2I (mL/min/m2) Sevo A 825 (172) * 606 (56) 434 (96) * †
Sevocris 880 (66) *  671 (176) 498 (156) * †
VO2I (mL/min/m2) Sevo A 173 (19) 142 (33) 143 (31)
Sevocris 175 (22) 162 (32) 162 (12)
O2ER (%) Sevo A 23 (7) 24 (6) 35 (12) * †
Sevocris 20 (3) 25 (6) 36 (13)* †
Temp (°C) Sevo A 38.3 (0.4) 38.4 (0.5) 38.5 (0.5)
Sevocris 38.6 (0.6) 38.6 (0.4) 38.7 (0.5)
Mean (SD); RR=respiratory rate; P peak=airway peak pressure; P plato=airway plato pressure; ComplDyn=dynamic compliance; Vt=tidal volume; 
EtCO2=end-tidal CO2; pH art=arterial pH; PaCO2=partial pressure of arterial CO2; PaO2=partial pressure of arterial oxygen; SaO2=arterial oxygen 
saturation; Lactate=arterial lactate; PvO2=partial pressure of mixed venous oxygen; SvO2=mixed venous saturation; DO2I=oxygen delivery index; 
VO2I=oxygen consumption index; O2ER=oxygen extraction ratio; Temp=temperature. * P<0.05 compared to 1 MAC; † P<0.05 compared to 0.5 MAC.536
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Table 4 - MAC (means±SD) results and methods employed in previous studies of pigs on sevoflurane.
Reference Age 
(weeks) 
Weight 
(Kg) 
Anesthesia protocol Nociceptive 
stimulation
Temperature 
(°C)
MAC 
(%)
Lerman et al.8 newborn 2.1±0.4 mask induction hoof coronary 
ligament clamping
37.5-38.5 2.12±0.39
Allaouchiche et al. 9 12-14 23±2 after ketamine and 
propofol
dewclaw 
clamping
38.6±0.6 2.4
Hecker et al. 10 NS 30.8±2.6 3 h after azaperone, 45 
min after propofol
dewclaw 
clamping
38.1 2.53±0.47
Manohar and Parks11  22-25 58.7±1.8 mask induction tail clamping 39.7±0.1 2.66±0.6
Moeser et al. 12 9 19±4 mask induction dewclaw clamping 38.1 3.5±0.17
Holmström and 
Åkeson 13
NS 20.1±0.7 90 min after 
propofol
dewclaw 
clamping
38.0±0.2 4.4±0.1
NS=not stated.
levels of carbon dioxide, which may influence cardiovascular 
function. The decreases in the oxygenation parameters, 
verified with the increases in MAC, may be associated 
with cardiovascular depression. The changes were more 
pronounced when MAC was raised to 1.5, contributing to 
a significant decrease in SvO2 and PvO2, while the oxygen 
extraction rate increased. Lactate remained unchanged with 
1.0 MAC and increased slightly with 1.5. 
No lung histopathological changes were associated with 
the two compositions of sevoflurane tested. The literature 
describes how sevoflurane may be degraded by metallic 
substances resulting in fluoridric acid, which may cause 
damage to the respiratory tract mucous membrane when 
inhaled, and many other fluoride-degrading products. To 
inhibit acid formation, substances such as water and, more 
recently, propylene glycol have been added to sevoflurane. 
A test conducted with a sevoflurane sample with 260 ppm 
of propylene glycol, heated to a temperature above 60°C in 
the presence of alumina, did not show significant change 
in the content of individual and total impurities when 
compared to those of the dry sevoflurane. The fluoride 
content of this sample was 0.051 µg/mL, which complied 
with specifications set by the USP Pharmacopoeia Forum, 
which determines a maximum fluoride limit of 2 µg/mL. 2
The exact mechanism through which propylene glycol 
stabilizes sevoflurane is not entirely clear, but it is possible 
to infer that propylene glycol and the Lewis acid form a 
compound that is highly efficient for blocking the action of 
metallic impurities on sevoflurane.
With regard to the possible toxicological effects of 
propylene glycol, hyperosmolality lactic acidosis, a central 
nervous system dysfunction, and cardiovascular disturbances 
were observed in patients receiving etomidate in a 35% 
propylene glycol vehicle.21, 22 In the present investigation, the 
sevoflurane contained 0.026% of propylene glycol, which is 
far less than the amount contained in etomidate formulation. 
 Moreover, after a study conducted by Bau et al. in which 
propylene glycol was a constituent of an aerosol formulation, 
the authors concluded that, under normal conditions of 
exposure, propylene glycol via inhalation is of limited 
toxicological relevance.23
In conclusion, propylene glycol as a sevoflurane additive 
can be used as safely as water as an additive, at least in terms 
of hemodynamic and pulmonary effects. 
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